Pfizer argues for regulatory coherence with orphans, like tafamidis
This article was originally published in Scrip
Executive Summary
In responding to the rejection on 25 January by English health ministers its one of its rare disease drugs, Vyndaqel, Pfizer took a side-swipe at the discrepancies between national and EU-level drug regulators, before insisting that it would continue to trying to get the drug to market in the UK.